Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation
Launched by UNIVERSITY HOSPITAL TUEBINGEN · Nov 25, 2024
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of surgery on blood clotting in patients with meningiomas, which are usually benign brain tumors. Although these tumors are not cancerous, surgery to remove them can lead to complications such as blood clots. The researchers want to understand how the removal of the tumor affects how blood clots form and how platelets (the cells that help blood clot) work. To do this, they will collect blood samples from patients before and right after their surgery for meningioma, as well as from patients undergoing similar surgery for another type of brain tumor called glioma.
If you or a loved one is between the ages of 65 and 74 and is scheduled for surgery to remove a meningioma or glioma, you might be eligible to participate in this trial. Participants will need to provide written consent to join the study. Throughout the trial, your health will be monitored, and you’ll be contributing valuable information that could help improve understanding of risks related to blood clotting after brain surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients undergoing resection for meningioma or
- • Patients undergoing resection for glioma or
- • Healthy controls
- • written consent for study participation
- Exclusion Criteria:
- • -
About University Hospital Tuebingen
University Hospital Tübingen is a leading academic medical institution in Germany, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its multidisciplinary expertise and cutting-edge facilities to develop new therapeutic strategies and improve patient outcomes. With a strong focus on translational medicine, University Hospital Tübingen collaborates with various stakeholders, including pharmaceutical companies and research organizations, to facilitate the efficient and ethical conduct of trials across a wide range of medical disciplines. Their dedication to patient-centered research and rigorous scientific standards positions them at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tuebingen, Baden Wuerttemberg, Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported